HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study

Inclusion Criteria:

Willing and able to provide informed consent and comply with all study requirements
Age ≥ 40 years of age
Stable, symptomatic heart failure with preserved ejection fraction and a H2FpEF Score ≥4
Presence of non-malignant inferior vena cava obstruction, a unilateral or bilateral chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter defined by screening MRV, CTV and confirmed by a 50% reduction in luminal area as assessed by intraprocedural IVUS.
Previous (>6 months) history of ilio-femoral and/or lower extremity deep venous thrombosis associated with a residual ilio-femoral venous obstruction ≥50% by MRV, CTV.
Clinically significant venous obstruction meeting CEAP Clinical classification ≥3.
Negative pregnancy test in females of child-bearing potential

Exclusion Criteria:

Subject hospitalized for acute compensated heart failure within 60 days prior to enrollment
Presence of history of clinically significant pulmonary emboli within 6 months prior to enrollment.
Subject has any permanent neurologic defect that may cause non-compliance with the protocol
Subject has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous).
Subject has an allergy to contrast media that cannot be adequately pre-treated prior to the required diagnostic and/or endovascular procedures.
Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.
Subject has renal failure or chronic kidney disease with glomerular filtration rate (GFR) ≤ 30 mL/min or Modification of Diet in Renal Disease (MDRD) study equation result of ≤ 30 mL/min per 1.73 m2.
Subject has white blood cell (WBC) count < 3.0 (3000 cells/mm3) within 7 days prior to index procedure.
Subject has a platelet count < 80,000 cells/mm3 or > 700,000 cells/mm3 ≤ 7 days pre procedure; uncorrected hemoglobin of ≤9 g/dL.
Subject has known or suspected active systemic infection evidenced by WBC > 14.0 (14,000/mm3).
Subject is currently participating in another investigational drug or device study.
Subject intends to participate in another investigational drug or device study within 30 days after the index procedure.
Subject has moderate or severe pulmonary disease (i.e., COPD) considered by Investigator to be a major contributing factor to the subject's exertional dyspnea